Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation

NCT03153514 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Prematurely terminated due to poor accrual

Conditions

Chronic Lymphocytic Leukemia
Richter's Transformation

Interventions

BIOLOGICAL: Obinutuzumab

Sponsor

German CLL Study Group

Collaborators

[object Object]